



(51) International Patent Classification:

A61K 39/39 (2006.01) C07K 7/00 (2006.01)  
A61K 47/30 (2006.01) C07K 14/705 (2006.01)  
A61P 21/04 (2006.01) A61K 39/00 (2006.01)  
A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2024/021269

(22) International Filing Date:

25 March 2024 (25.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/492,165 24 March 2023 (24.03.2023) US

(71) Applicant: **COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC.** [US/US]; 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US).

(72) Inventors: **ELHOFY, Adam**; c/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US). **WODARCYK, Greta**; c/o Cour

Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US). **BOYNE, Michael**; c/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US).

(74) Agent: **NEVILLE, Katherine, L.**; MARSHALL, GERSTEIN & BORUN LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: TOLERIZING IMMUNE MODIFYING NANOPARTICLES FOR MYASTHENIA GRAVIS TREATMENT




Fig. 3

(57) Abstract: The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))